Global oncology drug spending is expected to hit $441B by 2029 despite patent expirations later in the decade. Read more here ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

Q1 2025 Earnings Call Transcript May 12, 2025 Quanterix Corporation beats earnings expectations. Reported EPS is $-0.42, ...

Investors seeking the next breakthrough in precision oncology may want to take note of Nuvectis Pharma (NASDAQ ... all development-stage biotechnology companies, significant risks remain.

with over 25 years of experience in Oncology Pharma/Biotech. Dr. Vitoc held leadership roles at Bayer, Astellas, Cephalon, Novartis and Incyte and has managed and supported over 20 early ...

Pharma companies are expected to report healthy revenue growth of 11-13% in the fourth quarter of FY25, driven by strong traction in niche US generic drugs, steady domestic performance in a ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be ...

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology ...

Biopharma companies had to slow down many oncology clinical programmes and indeed ... TransCelerate BioPharma, a non-profit collaboration comprised of 20 of the largest biopharmaceutical companies ...